SPL-108 mitigates metastasis and chemoresistance in tubo-ovarian carcinoma
SPL-108 treatment has anti-metastatic properties and may play a role in chemoresistance in preclinical models of TOCs independent of CD44 expression. Ongoing in vitro and in vivo studies will help guide further clinical development of SPL-108.
Authors
- Kari Hacker
- Douglas A. Levine (ORCID: https://orcid.org/0000-0003-1038-8232)
- Elke Van Oudenhove (ORCID: https://orcid.org/0000-0001-9913-3898)
- Selim Mısırlıoğlu (ORCID: https://orcid.org/0000-0002-5390-6637)
- Olivia D. Lara (ORCID: https://orcid.org/0000-0002-3540-5804)
- Luana Pereira (ORCID: https://orcid.org/0009-0005-5998-4117)
Institutions
- University of North Carolina at Chapel Hill (US)
- NYU Langone Health (US)
Publication Details
- Journal
- Translational Oncology
- Published
- 2024-11-05
- DOI
- https://doi.org/10.1016/j.tranon.2024.102168
- Citations
- 1
- Primary Topic
- Ovarian cancer diagnosis and treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.54
Funders
- U.S. Department of Defense
- V Foundation for Cancer Research
- Honorable Tina Brozman Foundation
- National Cancer Center
- National Institutes of Health